Pharmaceutical compositions for treating Alzheimers disease are disclosed. The pharmaceutical compositions include a compound having the general formula:and a pharmaceutically acceptable carrier. Methods for treating Alzheimers disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid β-peptide (Aβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.
